胰岛素强化治疗对改善初诊2型糖尿病患者胰岛素抵抗的疗效分析

目的 评价三种短期胰岛素强化治疗改善不同胰岛素抵抗状态初诊2型糖尿病(T2DM)患者胰岛β细胞功能的效果.方法 初诊T2DM患者98例,分为存在胰岛素抵抗(IR)组(HOMA-IR≥5)和不存在胰岛素抵抗(Non-IR)组(HOMA-IR＜5);分别接受持续胰岛素皮下输注(CSⅡ)、门冬胰岛素加甘精胰岛素(glar)、门冬胰岛素30注射液(aspart 30)强化治疗,IR-CSⅡ组20例,IR-glar组22例,IR-aspart 30组23例;Non-IR-CSⅡ组10例,Non-IR-glar组12例,Non-IR-aspart 30组11例.测定6组治疗2周前后空腹血糖(FPG)、空腹C肽(C-P)、餐后2 h血糖(2 hPG),采用空腹C-P水平计算β细胞功能指数HOMA-islet(C-P)]和胰岛素抵抗指数HOMA-IR(C-P)].结果血糖达标时间、胰岛素用量、低血糖发生频率在CSⅡ组少于glar组和aspart 30组(P＜0.05或＜0.01),glar组与aspart 30组比较差异无统计学意义(P均＞0.05).达标时Non-IR组胰岛素日用量低于同种治疗方式的IR组(P均＜0.01),△HOMA-islet(C-P)高于IR组(P均＜0.05),△HOMA-IR(C-P)低于IR组(P＜0.05);CSⅡ组△HOMA-IR(C-P)(IR组1.79±0.15,Non-IR组1.51±0.09)和△HOMA-islet(C-P)(IR组4.01±0.21,Non-IR组4.35±0.23)高于glar组(IR组1.63±0.21、3.86±0.12,Non-IR组1.40±0.19、4.03±0.18)和aspart 30组(IR组1.61±0.13、3.88±0.32,Non-IR组1.42±0.11、4.01±0.14,P＜0.05或＜0.01).结论 三种胰岛素强化治疗方式均可改善伴有高血糖的初诊2型糖尿病患者胰岛β细胞功能,减轻胰岛素抵抗,尤以CSⅡ效果更好.但有明显胰岛素抵抗的患者治疗效果欠佳.

Effect of three intensive insulin treatments on newly diagnosed type 2 diabetes in different insulin resistant status

Objective To investigate the effects on the improvement of the function of islet β cell by three intensive insulin treatments on newly diagnosed type 2 diabetes(T2D) in different insulin resistant status.Methods Ninety-eight patients of newly diagnosed T2D were divided into two groups:group with overt insulin resistant status ( IR group) ( HOMA-IR ≥ 5 ); group without overt insulin resistant status ( Non-IR group) ( HOMA-IR ＜ 5).According to the condition of patient,there were six subgroups:IR-CSⅡ group ( n = 20 ); IR-glar group ( n = 22 );IR-aspart 30 group (n=23); Non-IR-CSⅡ group (n= 10); Non-IR-glar group (n=12); Non-IR-aspart 30 group (n = 11 ).Subgroups were treated with continuous subcutaneous insulin injection (CSⅡ group),insulin aspart plus insulin glargine ( glar group),and insulin aspart 30 injection ( aspart 30 group) for two weeks,respectively.The levels of fasting plasma glucose (FPG) ,fasting C-peptide(C-P) ,2 h plasma glucose (2 hPG) were measured and homeostasis model assessments of beta cell (HOMA-β) and homeostasis model assessments of insulin resistance ( HOMA-IR) were calculated using fasting C-P.Results The time of blood glucose recover,insulin dosage and the incidence of hypoglycemia of CSⅡ group were lower than those of the glar group and aspart 30 group( P ＜ 0.05 and P ＜0.01 ,respectively).However,there were no significant difference between the glar-group and aspart 30 group ( P ＞ 0.05 ).The insulin dosage of Non-IR-subgroups was significantly lower than the IR-subgroups ( P ＜ 0.01 ).The △HOMA-IR(C-P) of Non-IR-subgroups was lower than the IR-subgroups ( P ＜ 0.05 ).The △HOMA-islet(C-P) of the Non-IR-subgroups was higher than the IR-subgroups ( P ＜ 0.05 ).The △HOMA-IR(C-P) ( 1.79 ± 0.15 and 1.51 ±0.09 in IR and non-IR group,respectively) and △HOMA-islet(C-P) (4.01 ±0.21 and 4.35 ±0.23 in IR and Non-IR group,respectively) of the CSⅡ group were higher than those of the glar group (1.63 ± 0.21 and 1.40 ±0.19 of △HOMA-IR (C-P) and 3.86 ± 0.12 and 4.03 ± 0.18 of △HOMA-islet(C-P) in IR and Non-IR group,respectively) and aspart 30 group ( 1.61 ± 0.13 and 1.42 ± 0.1 1 ) △HOMA-islet (C-P) and 3.88 ± 0.32 and 4.01 ±0.14of△HOMA-islet(C-P)inIRandNon-IRgroup,respeetively)(P＜0.05).Conclusions Thethree intensive insulin treatments for newly diagnosed T2D accompanied with high blood glucose may improve the function of β cell and alleviate insulin resistance,especially the CSⅡ.However,the efficacy on T2D with overt insulin resistant status is limited.